Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Competing interests DB received presentation fees (TEVA, Novartis and Pfizer), travel fees (Allergan, TEVA, Pfizer, Abbvie and Lundbeck), advisory board fees (Novartis, Lilly, Teva, Lundbeck, Pfizer and Abbvie) and participated in clinical trials (TEVA, Lundbeck, Novartis, Lilly and Novo Nordisk Foundation) outside of the submitted work
About the study The current study performed a randomized, double-blind, crossover trial at the Research Institute of the McGill University Health Centre in Montreal, Quebec, Canada, to investigate whether semaglutide improved glycemic control and other nonglycemic outcomes in patients with T1D and using AID
In 2006, the development of tesaglitazar was terminated on the basis of an estimated benefit/risk profile that was not expected to be superior to existing therapies
Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women
US$ 28.18
US$ 28.00
US$ 29.52
US$ 26.12
US$ 22.03
US$ 26.67
US$ 28.08
